It was a good week for venture dealmaking among New England’s tech and life sciences firms.
—Needham, MA-based Stata Venture Partners led a $7 million Series B financing round for NABsys, a Providence, RI-based firm developing a DNA sequencing technology that employs silicon chips for rapid electronic detection of DNA sequences.
—Boston-based Battery Ventures sold Woburn, MA-based analytic instrument maker Nova Analytics, which it helped buy out in 2003, for an undisclosed sum to White Plains, NY-based ITT.
—EveryScape, a Waltham, MA-based operator of a website providing navigable, 360-degree views of metropolitan, suburban, and rural areas, raised $6 million in a Series C funding round led by SK Telecom Americas, and joined by Draper Fisher Jurvetson and Dace Ventures.
—North End Technologies, a robotics and communications company in Waltham, raised $2.5 million from Castile Ventures, company executives, and angel investors, and converted $1.8 million in preexisting debt to equity, according to CEO Brad Kayton.
—Boston-based Fluent Mobile, maker of the iPhone news-aggregating app Fluent News Reader, raised $1.25 million in equity funding, according to a regulatory filing.
—Milwaukee, WI-based Merge Healthcare (NASDAQ: MERG) made a $6.05 per share buyout offer for Boston-based radiology information management company Amicas (NASDAQ: AMCS). Amicas’ board of directors deemed the offer risky, though, and urged shareholders to accept a preexisting $5.35 per share offer from the private equity firm Thoma Bravo.
—Cambridge, MA-based e-commerce firm Allurent raised $2 million in its third round of venture capital. Contributors the round, all return investors, included Polaris Venture Partners and a group of angel investors.
—Bloomberg reported that Waltham-based research equipment maker Thermo Fisher Scientific (NYSE: TMO) made an unsolicited $6 billion bid to acquire Billerica, MA-based Millipore (NYSE: MIL), a maker of diagnostic and laboratory equipment.
—Currensee, the Boston-based social network for currency traders, closed an $8 million Series B financing round led by existing investor North Bridge Venture Partners and joined by new investor Egan Managed Capital. Only $6 million of that was new money, as $2 million consisted of Series A funds converted to Series B terms.
—Cambridge-based cancer drug developer Aveo Pharmaceuticals indicated in an SEC filing that it aims to price its planned 7-million-share IPO at $13 to $15 per share.
—Billerica-based biomedical instrument maker Seahorse Bioscience closed a $5 million Series D financing round. Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, FLIR Systems, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures, and HLM Venture Partners contributed to the round.
—LED maker Luminus Devices, also of Billerica, raised $19 million in Series F funding from return investors including Argonaut Private Equity, Braemar Energy Ventures, Paladin Capital Group, and Stata Venture Partners.